Asia-Pacific, Development & Aid, Headlines, Population

CHINA-SCIENCE: Foreign Gene Hunters Beware

Li Hui and Wang Jue

BEIJING, Nov 5 1997 (IPS) - Gene-hunting foreigners may soon be unable to forage as freely as they did before in China. Awaiting final approval from the State Council is a draft of new regulations controlling the export of human genetic material.

While details of the regulations are still unavailable, officials from the public health ministry and the State Science and Technology Commission (SSTC) say these are aimed at strictly restricting the export of disease family material, while encouraging work on such material to be conducted within China.

Because of its large and diverse population, China attracts gene researchers from all over the world.

The country of more than 1.2 billion people also has more types of epidemic and endemic diseases than elsewhere, says Prof. Du Ruofu of the Genetic Research Institute of the Chinese Academy of Sciences.

In recent years, foreign researchers visiting China have reportedly conducted mass sampling in areas with distinct local epidemics, either through collaboration projects with a Chinese medical institute or by hiring local workers to do the collecting.

These gene hunters have not only collected gene samples from families struck by certain diseases, but also the families’ medical records.

But families who were approached for such samplings and information gathering were often not informed of the intended use of the materials taken from them, says Prof. Chen Zhu of the Chinese Human Genome Project, who is known for his work on the gene diversity of Chinese minorities. No consent forms were offered to the families, he says.

In an article published earlier this year by ‘Genome Digest’, Chen warned foreign gene-hunting companies of the danger of “legal and ethical complications” when they buy disease family material from China.

He says all family samples from China that became part of research papers published recently in foreign scientific journals were obtained by illegal means.

This is because Chinese laws forbid the export of any human blood, urine, tissue and organ samples and products unless approved by the Ministry of Health.

Yu Xiucheng, director of the ministry’s division of scientific and technological exchanges, and the only one authorised to issue such approvals, has denied giving any permit for the export of any gene sample. Yu also says any approval obtained at provincial level is invalid.

But just recently, Chen says, foreign scientific journals published a research study based on samples that had been collected from several large Chinese families with histories of disease such as asthma and diabetes. The samples have been widely used by companies and laboratories in the successful mapping or cloning of disease genes.

The new regulations are expected to be more stringent than the old laws. Xu Xinlai of the State Science and Technology Commission confirms this, pointing out that while the previous regulations targetted mainly blood products, the new rules will specify genetic materials as restricted exports.

But both Chinese scientists and officials say China is not about to close its doors to joint research projects with foreigners.

Biologist Qiang Boqin, who is co-leader with Chen Zhu of China’s Human Genome Project, says Chinese scientists welcome collaboration with foreigners, so long as these are made on equal terms and would work to mutual benefit.

“We are not making excessive demands,” he said. “What we ask for is a fair sharing of benefits that should be distributed according to contributions by each participant.”

Indeed, Chinese scientists believe international collaboration is a shortcut to promote Chinese gene research. They hope to take advantage of the country’s special genetic resources in finding research partners from whom they could have access to advanced technology.

But compromises may be necessary. While international projects usually focus on the diversity of human genomes, China’s genetic research — carried out at present by 20 research groups — are mainly on the gene diversity of Chinese minorities and disease- related genes.

Prof. Qiang Boqin says the ideal collaboration between Chinese and foreigners would be like this: the foreign partner brings into China the necessary technical equipment with which to test the disease family materials collected locally. When a chemical drug is developed, the Chinese partner gets a due share of the sales of the product.

“Our prerequisite (for projects) is simple and constant,” said the health ministry’s Yu Xiucheng. “The cooperative agreement must make it clear that both sides are equal in the research and in sharing the benefits and achievements — or there will be no approval from us.”

 
Republish | | Print |

Related Tags